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The complement system is an important humoral defense mechanism that plays a relevant role against microbial
agents, inflammatory response control, and immunocomplex clearance. Classical complement pathway activation is antibody-
dependent. The C4 component participates in the initial step of activation, and C4 expression is determined by 2 pairs of
allotypes: C4A and C4B. Deficiencies in C4 allotypes have been associated with several diseases.
The aim of the present review is evaluate the reported data in the literature regarding specific C4A and C4B deficiencies
and characterize their clinical relevance.
We searched the MEDLINE and LILACS databases. Papers referring to total C4 deficiency without allotype evaluation
and case reports of primary C4 deficiency were not included.
Deficiencies in C4 allotypes have been associated with Mycobacterium leprae infection, erythema nodosum, systemic
sclerosis with anti-topoisomerase I antibodies, intermediate congenital adrenal hyperplasia with DR5 genotype, diabetes
mellitus type 1 with DR3,4 genotype, and diabetes mellitus with antibodies against islet cells. C4 allotype deficiency is also
related to C4B deficiency and autoimmune-associated diseases, such as systemic lupus erythematosus, or diseases with an
autoimmune component, such as autism. Some reports associate C4A with thyroiditis after delivery as well as limited and
systemic sclerosis without anti-topoisomerase I antibodies. However, the studies with C4A and C4B have been concentrated
in isolated populations, and some of the studies could not be reproduced by other authors.
KEY WORDS: C4 allotypes. C4A. C4B. C4. Complement. Complement deficiency.
The complement system is com-
prised of at least by 30 proteins,7 form-
ing an important mechanism of hu-
moral defense by the immune system.
It activates in defense against micro-
bial agents, in the control of the im-
mune response, and in the clearance of
immune complexes. It can be activated
by 3 pathways: classic, alternative,
and by lectins.
The classic pathway depends on
the presence of antibody. Therefore, it
is an effector system of high
specificity. Viruses, DNA, C-reactive
protein, and mitochondrial membranes
can activate this pathway, independent
of the antibody. Furthermore, fungi,
polysaccharides, viruses, and cells in-
fected by viruses can activate the path-
way directly. The lectin pathway may
be initiated by the linkage of mannan-
binding lectin (MBL) to mannose and
N-acetyl-glucosamine residues on sur-
faces of microorganisms. When MBL
binds to these sugars, they activate the
serine proteases of mannose (MASP-1
and MASP-2). After that, C4 is cleaved
into C4a and C4b, and C2 into C2a
and C2b. All the pathways converge to
C3 activation, and consequently, the
membrane attack complex (MAC)2 is
formed.
Receptors for the complement sys-
tem components are largely distrib-
uted on the surface of tissue and blood
cells. In addition to the mediated cy-
tolysis by MAC, the action of comple-
ment is mediated by 3 products that are
generated during the activation of
ligands by specific receptors that act
in several cells. The regulation of the
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complement system is controlled by a
group of plasma proteins, and cells use
these regulator proteins, which are lo-
cated on their membranes, to defend
themselves from the MAC systems.
Most of the complement proteins
are produced in the liver; nevertheless,
some other cells, such as monocytes,
T cells, macrophages, granulocytes,
skin fibroblasts, and keratinocytes that
produce C3, can also synthesize these
components.2,3
The complement system is impor-
tant to host biological defense, as is
evident when patients with comple-
ment component deficiencies show an
increased predisposition for infections
and diseases.
The C4 molecule (204 kDa) is pro-
duced in the liver, and its concentra-
tion in the plasma is about 75 mg/mL2.
This molecule is synthesized as a sin-
gle chain and then is processed into 3
polypeptide chains (α, β, γ). The α
chain has an intramolecular thioester
bond. C4 is cleaved by C1s, forming
C4a and C4b. This reaction allows a
covalent binding between the acti-
vated protein and the cellular surface
or the receptor molecule.2
The expression of C4 is determined
by 2 allotypes: C4A and C4B. They
are coded by 2 adjacent genes that are
located on the short arm of chromo-
some 6. These genes are close to genes
that code for the enzyme 21-hydroxy-
lase (21-OH), the C2 component, and
the B factor (Bf), all of which are com-
ponents of the major histocompatibil-
ity complex class III (MHC class III)2,4
(Figure 1).
The C4 fraction is one of the most
polymorphic molecules of the MHC
class III, with about 35 allotypes hav-
ing been described.5 C4 polymor-
phism is important for binding the
large diversity of antigen-antibody
complexes.
At the primary response, recogni-
tion of the antigen by the antibody is
amplified by the classic pathway of
complement activation, in which the
cleavage of C4 into C4a and C4b by
C1 are some of the first steps. The bind-
ing efficiency depends on the C4 al-
lotype and the nature of the antigen or
antibody molecule. The C4b fraction
from the C4A allotype preferentially
binds amide groups to amino groups,
while C4b from C4B makes ester
bonds using carbohydrates or hy-
droxyl groups from amino acids (ser-
ine, threonine, tyrosine). This selectiv-
ity seems to be related to the electro-
static and stereochemical interactions
between the isotypic regions of the
C4’s a chain and the receptor mol-
ecule.5,2,6 This C4 polymorphism also
suggests an important involvement in
the autoimmune diseases.6
The C4A and C4B allotypes have
90% homology. At the a chain region
called C4d, there are 4 amino acids at
positions 1101 to 1106 that are re-
sponsible for the structural and func-
tional differences of the 2 allotypes.5
The aim of the present study is to
describe the clinical significance of a
partial deficiency of C4 and to evalu-
ate the papers that associate human
diseases with specific deficiencies of
the C4 allotypes.
METHOD
We performed an extensive litera-
ture review of the last 10 years using
the MEDLINE and LILACS databases.
Publications associated with C4 defi-
ciency allotypes and human diseases
were included. Furthermore, the key
words C4 allotypes and diseases were
used. We excluded papers concerning
a primary deficiency with total ab-
sence of C4 (C4 congenital defi-
ciency), which are very rare in the
medical literature. Studies about C4
deficiency without the allotype evalu-
ation were also not considered.
RESULTS
Deficiencies in C4 allotypes that
are associated with human diseases
and the methodology applied for de-
termining the plasma levels comple-
ment components or allotype
genotyping are shown on Table 1.
Total deficiency of C4 and its
allotypes
Complement deficiency, in particu-
lar of the C4 fraction, has been the
subject of studies of several human
diseases. Deficiencies in C4 allotypes
occur in 0.1% to 0.3% of the popula-
tion as result of deletion, genetic con-
version, or silent mutations.5 C4 defi-
ciencies have been shown to be in-
volved in the following diseases: sys-
temic lupus erythematosus (SLE),6 au-
tism,7,8 hyperactivity,9 erythema
nodosum in leprosy,10,11 postpartum
thyroiditis,12 diffuse and limited sys-
temic sclerosis,13 schizophrenia,14 type
1 diabetes mellitus,15 congenital adre-
Figure 1 - Schematic representation of human major histocompatibility com-
plex class III.
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nal hyperplasia,16 rheumatoid arthri-
tis,17 contact dermatitis,3,18 infection
with encapsulated bacteria,19 and sud-
den infant death4 (Table 1).
C4 deficiencies have been associ-
ated with an increased susceptibility to
bacterial and viral infections, the pre-
disposition to chronic active hepatitis
15
 and vitiligo 8.
However, repeated infections were
not always found in people with defi-
ciencies of the components on the
classic pathway, exemplifying the im-
portance of the alternative pathway for
eliminating the majority of the micro-
organisms.2
A deficiency in the C4A allotype
was found to be associated with SLE,
postpartum thyroiditis, diffuse sclero-
sis without the anti-topoisomerase I
antibody (ATIA), and limited sclerosis.
A deficiency in the C4B allotype was
found to be associated with autism,
erythema nodosum leprosum, diffuse
sclerosis with ATIA, congenital adre-
nal hyperplasia, type 1 diabetes
mellitus, hyperactivity, and rheuma-
toid arthritis (Table 1). Both C4A and
C4B allotype deficiencies were not as-
sociated with sudden infant death,
contact dermatitis and nickel dermati-
tis. Schizophrenia and infections
caused by encapsulated bacteria were
not related to C4B allotype deficiency
and it was not evaluated for C4A allo-
type deficiency.
Autoimmune diseases and C4
allotypes
The presence of high levels of cir-
culating immune complexes in SLE
has been associated with C2 and C4
function in the process of removing of
these complexes, which suggests that
deficiencies of these proteins can oc-
cur in autoimmune diseases.2 The cor-
relation of high levels of immune
complexes and deficiencies of C2 and
C4 is due to the fact of these proteins
are fundamental to the formation of
C3-convertase in the classic pathway
and to immune complex dissociation.
Studies in different populations
that have inheritable total C4 deficien-
cies, such as white Western Europeans,
Australians, Afro-Americans, Chinese,
Japanese, and mixed-race Mexicans,
reveal an increased predisposition to
SLE in these populations.6,8
Homozygous C4A deficiency is
observed in from 13% to 15% of
caucasian patients with SLE and in
only 2% of the normal population,
with a relative risk of 17.6 Partial or to-
tal C4B deficiency also contributes as
a risk factor. Total C4 deficiency has
been associated with SLE in more than
80% of the cases.10
Moulds et al. (1993)6 verified that
C4A and C4B levels in SLE change pro-
portionally to the disease activity. In pa-
tients with active disease, the levels of
C4A and C4B increase, while the levels
are reduced in the periods without activ-
ity, when compared with normal indi-
viduals. Additionally, the authors dem-
onstrated that partial deficiencies of one
C4 allotype do not modify the total
level of serum C4 protein, which means
that heterozygous individuals with C4A
deficiencies have increased levels of
C4B, while heterozygous individuals
with C4B deficiencies have increased
levels of C4A. The authors show in this
study that in blacks with SLE, the total
levels of C4, C4A, and C4B are higher
Table 1 - Literature data associating C4 allotype deficiency and other diseases (C4A and C4B).
Disease C4A deficiency C4B deficiency Methodology of detection References
Systemic lupus erythematosus related related enzyme-linked immunosorbent assay Moulds et al.6
Autism not related related enzyme-linked immunosorbent assay Warren et al.7
Electrophoresis with immunofixation Warren et al.8
Erythema nodosum in not related related Electrophoresis with immunofixation de Messias et al.10
Hansen’s disease and Western blot
Thyroiditis, postpartum related not related Electrophoresis with immunofixation Parker et al.12
Diffuse sclerosis With anti- not related related Electrophoresis with immunofixation Takeuchi et al.13
topoisomerase I antibody
Diffuse sclerosis without anti- related not related Electrophoresis with immunofixation Takeuchi et al.13
topoisomerase I antibody
Limited sclerosis related not related Electrophoresis with immunofixation and Takeuchi et al.13
polymerase chain reaction
Congenital adrenal hyperplasia not evaluated related Radioimmunoassay Parlato et al.16
Diabetes mellitus type 1 not evaluated related Electrophoresis and immunoprecipitation Deschamps et al. 15
Hyperactivity not related related enzyme-linked immunosorbent assay Warren et al.9
Rheumatoid arthritis not related related Pamela et al.17
Sudden infant death not related not related Electrophoresis and polymerase chain reaction Opdal et al.4
Schizophrenia not evaluated not related Polymerase chain reaction Schroers et al.14
S. pneumoniae not evaluated not related Electrophoresis with immunofixation Cates et al.19
H. influenzae
N. meningitidis
Contact dermatitis not related not related enzyme-linked immunosorbent assay Brand et al.3
Nickel dermatitis not related not related Electrophoresis with immunofixation Orecchia et al.18
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than in Caucasians, independent of dis-
ease activity (total C4 level in Afro-Eu-
ropean with active disease was close to
40 mg/dL while in whites was 28 mg/
dL). This racial difference is more impor-
tant in SLE evaluation than is the con-
tribution of homozygous or hetero-
zygous C4 deficiency.
Lhotta et al. (1996)20 concluded
that in glomerulonephritis, the pre-
dominance of glomerular C4A depo-
sition is due to a higher affinity of
C4A to the proteins of immune com-
plexes. The same affinity is not ob-
served with C4B.
Paimela et al. (1996)17 studied 73
cases of rheumatoid arthritis. They
found a correlation between the prog-
nostic factor of the disease and the
alleles of complement: factor B (Bf)
and C4. Patients with C4B null allele
(and consequently C4B deficiency)
had higher disease activity with more
radiological progression than patients
with C4A null allele or patients with-
out null allele. C4B deficiency was
also associated with a higher suscep-
tibility to adverse effects of the
antirheumatic therapy.17
Takeuchi et al. (1998)13 evaluated
the contribution of the C4A and C4B
allele polymorphism in the
pathogenesis of systemic sclerosis in
Japanese patients. A significant in-
crease of 44.4% in the frequency of
C4BQO (null alleles of C4B) in sys-
temic sclerosis with diffuse sclero-
derma was observed.
In systemic sclerosis with anti-
topoisomerase I antibodies (ATIA), a
50% increase of the incidence of
C4BQO was also verified. In contrast,
the presence of C4AQO was signifi-
cantly increased in limited sclero-
derma (53.8%) and in systemic sclero-
sis not associated with the presence of
ATIA. They concluded that C4BQO
and C4AQO are independent genetic
markers for each clinical subgroup of
systemic sclerosis and for the
positivity to ATIA.
Endocrine diseases and C4 allotypes
Based on the proximity of the C4
and 21-hydroxylase locci to the class
III region of the MHC, Parlato et al.
(1992)16 studied the relationship be-
tween C4 and enzyme deficiencies that
are important in cortisol synthesis. Al-
though there is a lack of evidence in
humans, it had been demonstrated in
mice that there is hormonal regulation
in the production of Bf and C4. De-
spite the few number of cases in the
study, these authors suggest that C4B
deficiency is associated with DR5+ in-
dividuals and low levels of Bf, and
C4B deficiency can be related to the
congenital adrenal hyperplasia, one of
the standard presentations of 21-hy-
droxylase deficiency. Recently, Gil et
al. (2002)21 observed C4 allotype de-
ficiencies associated with 21-hydroxy-
lase deficiency. A duplication of C4A
or C4B with increased serum levels
and the deletion of one pair of
allotypes, resulting in undetectable
levels of them, was also observed.
The association in diabetic rela-
tives between the risk for developing
diabetes and C4 deficiency, especially
C4B, was studied by Deschamps et al.
(1992).15 In a 8-year prospective study,
the authors found a significant risk
(relative risk of 112) for siblings of de-
veloping type 1 diabetes when they
had a DR3,4 genotype, antibodies to
islet cells, and a C4B deficiency
(C4BQO). In this study, 86% of indi-
viduals with this genotype presented
type 1 diabetes, while 25% without
C4B deficiency developed the disease
during the follow-up. Among the pa-
tients without autoantibodies but with
C4B deficiency, 4% developed the
disease. When they compared the in-
dividuals, 8.7% with C4B deficiency
developed diabetes and only 2.4% of
these individuals without this defi-
ciency developed it, independently of
the presence of the autoantibodies. In
DR3,4+ and C4B deficient individu-
als, 36% developed the disease com-
pared with only 8% of the DR3,4+
without C4B deficiency. Furthermore,
the DR3,4+ individuals with C4B de-
ficiency developed diabetes at a
younger age than did the group with-
out C4B deficiency (8.9 ± 1.42 years
versus 25 ± 4.9 years, p < 0.01). In
contrast, in individuals not DR3,4+
but deficient in C4B, 2% developed
the disease. Therefore, it is reasonable
to conclude that the C4B deficiency
is a risk factor of low importance for
type 1 diabetes mellitus when it is not
associated with the DR3,4 genotype.
Parker et al. (1996)12 evaluated the
association between the MHC class III
and DQ-MHC molecules in postpar-
tum thyroiditis, and they determined
the prevalence of Bf, C4A and C4B
allotypes in this condition. The fol-
lowing were evaluated: incidence,
prevalence, and clinical consequences
of postpartum thyroiditis in 2897 preg-
nant women in South Wales (United
Kingdom) between 1983 and 1989.
They compared 265 pregnant women
with high levels of circulating antithy-
roid antibodies with other 316 preg-
nant women having regular levels of
the circulating antithyroid antibodies.
They verified that postpartum thy-
roiditis is frequently associated with
C4A and Bf deficiencies and not to
deficiencies in C4B.
Psychiatric disorders
Warren et al. (1994)7 tried to corre-
late MHC to autism using plasma con-
centrations of C4 in autistic patients
and their relatives; these data were
compared with the results of the
plasma concentrations in normal per-
sons. In this study, they observed a sig-
nificant decrease in the plasma C4B
concentration in autistic patients (av-
erage of 14.7g/L) when compared with
the normal standard (average of 22.4
g/L). The plasma concentration of the
C4B in autistic relatives was also
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found diminished, but it was not sig-
nificantly lower. C4A concentrations
were normal in both groups.
Later (1995),8 the same authors
evaluated the C4B levels in autistic
patients, and they verified that the ac-
tivation of T DR+ cells was not asso-
ciated with the patient’s age, disprov-
ing a notion that in autistic patients,
the activation of T DR+ cells de-
creases with the aging. However, in
this study, it was also verified using
DR markers that there were DR+ T
cells, indicating T-cell activation, but
there was no increase in IL-2 receptor
expression in these cells, which is also
associated with T-cell activation.
These data indicate that T-cell activa-
tion is related to the decrease of plasma
C4B levels and, perhaps indirectly, to
the decrease of MHC class III expres-
sion. This conclusion was based on the
fact that C4 allotypes are located on
chromosome 6, near the MHC class III
and class II regions, which determine
the DR genotype of the T lymphocyte
(Figure 1). Nevertheless, an association
between C4A and T DR+ cells was not
found. This study provides strong evi-
dence that an autoimmune process, in-
volving C4B especially, is involved in
the genesis of autism, although this
disease has an unknown etiology.
The association of decreased C4B
levels was also observed in children
with attention-deficit hyperactivity
disorder 9.
One of the hypotheses regarding
the development of schizophrenia is
related to C4B deficiency. A study
demonstrated an increased expression
of HLA-B44 antigen in schizophrenic
patients´ mothers 14 and this finding
was significant when compared with
the control group. It was suggested
that the increased expression of HLA-
B44 in the mothers could induce an
abnormal maternal-fetal immune re-
sponse during the initial stages of preg-
nancy, and maternal antibodies would
challenge a neurological lesion which
results in schizophrenic children.6,14
Schroers et al. studied 176 patients
with schizophrenia and verified that
there were no significant differences
between these patients and a control
group regarding C4B deficiency
(n=145). Previous studies7 had shown
evidence of a relationship between ho-
mozygous C4B deficiency and schizo-
phrenia. Nevertheless, these authors
postulate the possibility that schizo-
phrenia could be associated with a de-
ficiency of a gene close to the C4 lo-
cus, considering the association of
schizophrenia with HLA-B44 and its
location on the same chromosome.
Dermatological diseases and C4
allotypes
de Messias et al. (1993)10 associated
C4B deficiency with erythema
nodosum leprosum (ENL). Erythema
nodosum leprosum results from anti-
body-mediated reactions and corre-
sponds to the Gell and Coombs type III
hypersensitivity. It is hypothesized that
these reactions could be linked to ba-
cillar destruction and antigen exposure,
resulting in stimulus of antibody pro-
duction and immune complex forma-
tion. These immune complexes activate
complement and neutrophil migration,
resulting in tissue destruction and vas-
culitis. The intensity of the ENL phe-
nomenon is associated with the produc-
tion of tumor necrosis factor (TNF) α.
In the complete clinical phenotype of
ENL, fever, malaise, painful lymphad-
enitis, erythematous plaques and nod-
ules, neuritis, arthritis, arthralgia, iritis,
orchitis, and other findings are ob-
served. The authors evaluated the asso-
ciation between some MHC class III
molecules, such as C2, Bf, C4A, C4B,
with leprosy in a South Brazilian popu-
lation. The results demonstrated that
there was not an increased C4B expres-
sion in leprosy patients with ENL com-
pared with a control group. All the ho-
mozygous C4B-deficient patients pre-
sented ENL, suggesting that C4B defi-
ciency leads to an abnormal immune
response to Mycobacterium leprae. The
deficiency in the immune complex
clearance results in ENL.
Brand et al. (1994)3 evaluated C4A,
C4B, and total C4 levels in the lymph
of 2 healthy volunteers after triggering
with a contact irritant for 7 days, and
they verified that the complement frac-
tions were not involved in the physi-
opathological mechanism of contact
dermatitis, but they were involved in
the inflammatory process and in the in-
teractions with the inflammatory
cytokines and soluble mediators that
arise in the regional lymph nodes. Con-
sequently, they concluded that there is
not a special involvement of comple-
ment system in the initial pathologic
mechanism of contact dermatitis.
Orecchia et al. (1992)18 studied the
polymorphism of the MHC class III
genes in 55 patients of different ages
having contact dermatitis. It was not
possible to establish a relationship be-
tween contact dermatitis stimulated
with different allergens and the MHC
class III molecules. However, from
their findings, they suggested a genetic
relationship between MHC and con-
tact dermatitis caused by nickel.
Other diseases
Opdal et al. (1994)4 evaluated the
involvement of partial deletion of C4
genes in sudden death of infants. In
this study, the authors could not prove
a relationship between C4 deficiency
and sudden infant death, but they ob-
served that children with C4A and
C4B deletion had a higher vulnerabil-
ity to lethal infections (p= 0.035) when
compared with normal children.
Cates et al. (1992)19 evaluated ho-
mozygous C4B deficiency and the oc-
currence of bacteremia or meningitis
caused by capsulated microorganisms.
Accordingly, they searched for C4B de-
ficiencies in 4 patient groups: patients
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with bacteremia, those with meningitis,
those who developed Haemophilus
influenzae type b (Hib) disease after Hib
polysaccharide vaccination, and pa-
tients less than 1 year old with menin-
gitis. Healthy adults served as controls.
Of the 257 patients, 2.3% were ho-
mozygous for C4B deficiency com-
pared with 3.7% in 349 controls. There-
fore, an association between ho-
mozygous C4B deficiency and menin-
gitis or bacteremia caused by encapsu-
lated bacteria was not observed.
CONCLUSION
The deficiency of C4 allotypes has
been associated with some diseases:
erythema nodosum in leprosy, sys-
temic sclerosis with ATIA, congenital
adrenal hyperplasia with DR5 geno-
type, type 1 diabetes mellitus with
DR3,4 genotype, and diabetes mellitus
with anti-islet cell antibodies. Some
association has also been noted be-
tween C4B and the activity in some
autoimmune diseases, such as SLE, or
in diseases with a supposed
autoimmune component in their gen-
esis, such as autism.
Regarding C4A, the studies demon-
strated an association with postpartum
thyroiditis and limited sclerosis and
systemic sclerosis without ATIA; how-
ever, with C4A as for C4B, the studies
are concentrated in isolated
populations, and some studies could
not be reproduced by other authors,
such as those concerning schizophrenia.
Thus, we conclude that additional
studies using standardized methods for
determining allotypes and genotypes
are required to characterize the asso-
ciation between C4 deficiencies and
human diseases.
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RESUMO
SAMANO EST e col. O envolvimento
dos alótipos de C4 na patogênese
das doenças humanas. Rev. Hosp.
Clín. Fac. Med. S. Paulo 59(3):
138-144, 2004.
O sistema complemento constitui
um importante sistema de defesa hu-
moral, exercendo papel relevante na
resposta contra agentes microbianos,
no controle da resposta inflamatória e
na depuração de imunocomplexos. A
ativação da via clássica é dependente
da formação do complexo antígeno-
anticorpo. O componente C4 do
complemento participa da etapa inicial
de ativação desta via e a sua expressão
é determinada por dois alótipos : C4A
e C4B. A deficiência dos alótipos de
C4 tem sido relacionada a várias
doenças.
O objetivo do presente estudo foi
avaliar os dados de literatura que des-
crevem as deficiências específicas de
C4A e C4B com a finalidade de carac-
terizar seu significado clínico.
Foi realizada uma ampla revisão
bibliográfica através do MEDLINE e
LILACS, avaliando-se os dados de li-
teratura. Excluiu-se estudos com a
avaliação de C4 total sem a análise
dos alótipos e relatos de caso isolados
de deficiência total de C4.
Verificou-se que a deficiência dos
alótipos de C4 está relacionada com
algumas doenças: hanseníase,
esclerose sistêmica com anticorpos
anti-topoisomerase I, hiperplasia
adrenal congênita intermediária com
genótipo DR5, diabetes mellitus tipo
1 com genótipo DR3,4 e diabetes
mellitus tipo 1 com anticorpos anti-cé-
lulas das ilhotas. Também foram obser-
vadas algumas associações entre C4B
e doenças auto-imunes como lupus
eritematoso sistêmico, ou que se supõe
terem um componente auto–imune
como o autismo. Estudos demonstra-
ram associações do C4A com tireoidite
pós-parto, esclerose limitada e
esclerose sistêmica sem anticorpos
anti-topoisomerase I. Porém, os estu-
dos dos alótipos de C4 se concentra-
ram em populações isoladas e alguns
destes não conseguiram ser reproduzi-
dos por outros autores.
UNITERMOS: C4A. C4B. C4.
Complemento. Deficiência de com-
plemento. Alótipos de C4.
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